Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer (Q82659209)
Jump to navigation
Jump to search
scientific article published on 23 November 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer |
scientific article published on 23 November 2011 |
Statements
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer (English)
G Sonpavde
V Matveev
J M Burke
J R Caton
M T Fleming
T E Hutson
M D Galsky
W R Berry
P Karlov
J T Holmlund
B A Wood
M Brookes
23 November 2011